Document is current
Any future updates will be listed below
-
Authors
Saarentaus, Elmo C. https://orcid.org/0000-0002-8475-7187
Karjalainen, Juha
Rämö, Joel T. https://orcid.org/0000-0002-6429-5149
Kiiskinen, Tuomo https://orcid.org/0000-0002-6306-8227
Havulinna, Aki S.
Mehtonen, Juha https://orcid.org/0000-0003-0554-4667
Hautakangas, Heidi https://orcid.org/0000-0002-5585-6856
Ruotsalainen, Sanni https://orcid.org/0000-0002-1631-4069
Tamlander, Max https://orcid.org/0000-0003-2249-0971
Mars, Nina
,
Toppila-Salmi, Sanna
Pirinen, Matti https://orcid.org/0000-0002-1664-1350
Kurki, Mitja
Ripatti, Samuli https://orcid.org/0000-0002-0504-1202
Daly, Mark
Palotie, Tuula
Mäkitie, Antti https://orcid.org/0000-0002-0451-2404
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
-
Funding
Funding for this research was provided by:
Suomen Lääketieteen Säätiö (3264)
Academy of Finland (312074)
- License Information
-
More Information
Article History
Received: 24 June 2021
Accepted: 26 September 2022
First Online: 18 January 2023
Competing interests
: S.T.S. reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant of GSK, outside the submitted work. All other authors declare competing interests.
